What Is Anorexia Nervosa?
Anorexia Nervosa (AN) is an eating disorder defined by a severe and irrational fear of gaining weight, even when the individual is significantly underweight. Individuals with AN have a mistaken perception of their body image, believing they are overweight despite being incredibly skinny. Individuals with AN tend to severely limit their food intake, resulting in harmful amounts of weight loss. They may also engage in compensatory behaviors such as excessive exercise, purging (self-induced vomiting), or using laxatives or diuretics to avoid weight gain.
AN is more than just food or weight; it is a complicated mental health problem with both psychological and physical manifestations. Individuals with AN may experience severe anxiety of losing control, a strong need for perfection, and low self-esteem. They may also have obsessive thoughts about food, calories, and weight that take up a large portion of their everyday lives.
Physically, AN can be devastating. Severe weight loss can cause a variety of difficulties, including nutrient deficits, bone loss, hormone imbalances, cardiovascular issues, and, in extreme cases, organ failure. The human body is not meant to sustain the level of starvation experienced in AN, and if not treated properly, the disorder can be fatal.
Despite the availability of several treatment options, including psychotherapy, nutritional counseling, and medication, AN relapse rates remain high. This emphasizes the need for further research into alternate therapy approaches that can assist in addressing the disorder's complex psychological and physiological components.
In recent years, there has been a growing interest in the possible function of cannabis and its principal components, cannabinoids, in the treatment of AN. This interest arises from cannabinoids' promising benefits on appetite regulation and anxiety reduction, as well as their ability to address some of the underlying causes contributing to the development and maintenance of AN.
What Is the Relationship Between the Endocannabinoid System and Anorexia Nervosa?
The ECS is a complicated system in our bodies that regulates many activities, including appetite, metabolism, and stress response. It is composed of cannabinoid-like chemicals produced naturally in our bodies, known as endocannabinoids, and their corresponding receptors, primarily CB1 and CB2.
New research reveals that people with AN may have anomalies in their ECS. These anomalies may contribute to the development and progression of AN.
Furthermore, investigations have identified variations in the availability of cannabinoid receptors and circulating endocannabinoids in the bodies of patients with AN vs healthy people. Some studies have also discovered links between these ECS abnormalities and specific AN symptoms, such as reduced body weight and increased emotional distress.
However, research in this area has produced contradictory results, most likely due to methodological discrepancies and limited sample sizes. Despite these differences, the overall findings indicate that the ECS may have a role in the underlying processes of AN.
Further study with consistent methodology and larger sample sizes is required to further understand the role of the ECS in AN and its potential as a biological marker or therapy target. In a nutshell, the ECS is a system in our bodies that governs vital activities such as appetite and metabolism. According to research, this mechanism may not work effectively in people with AN, contributing to the disorder's development and persistence. More studies are required to completely understand the role of the ECS in AN completely and how to target it for future therapies.
What Are the Potential Benefits and Risks of Cannabinoid Treatment for Anorexia Nervosa (AN)?
Since studies have shown anomalies in the endocannabinoid system (ECS) in people with AN, experts have looked into using exogenous cannabinoids (derived from the cannabis plant) as a potential therapy option.
Cannabinoids such as THC (tetrahydrocannabinol) and CBD (cannabidiol) are cannabis' primary active components. They interact with the ECS in our bodies, influencing a variety of physical and psychological functions.
Several studies have investigated the effects of cannabis treatment on persons with AN. The results have been mixed.
Some research reported positive outcomes, such as:
-
Improvement in eating disorder symptoms.
-
Reduced desire to engage in excessive physical exercise.
However, other research discovered no favorable effects or even potential dangers, such as:
-
Increased physical activity levels.
-
Changes in hormones connected to fat tissue.
These contradictory findings across multiple research could be attributable to a variety of factors:
-
The wide range of doses used in the studies.
-
Small number of participants.
-
Individual variations in how people respond to cannabis.
-
Importantly, none of the current research investigated the effects of CBD alone.
CBD is a non-psychoactive cannabinoid (it does not provide a "high") that is known to alleviate anxiety, a typical symptom in AN. Using CBD in conjunction with THC may help mitigate some of the negative effects associated with THC consumption.
What Are the Harms Associated With Cannabis Use in Anorexia Nervosa?
While the potential benefits of cannabinoid treatment for AN are intriguing, it is crucial to consider the potential harms associated with cannabis use in this population. Several studies have found that people who are genetically prone to developing AN may also be more likely to acquire a cannabis use disorder. In addition, case reports have shown that cannabis use can be associated with compensatory behaviors such as purging and excessive activity in people with the binge/purge subtype of AN. This phenomenon could be attributed to cannabis' appetite-stimulating effects, which could lead to counterproductive recovery scenarios if not managed properly.
Long-term cannabis usage has also been linked to a disorder called cannabinoid hyperemesis syndrome (CHS), which is characterized by recurring vomiting. Due to comparable symptoms, this illness may be ignored or misunderstood in people with the binge or purge subtype of AN.
Future studies on marijuana treatment for AN must include measures to examine compensatory behaviors and issues related with cannabis use. Furthermore, healthcare providers should be aware of the possible hazards and constantly monitor people with AN who use cannabis, whether recreationally or as part of a therapeutic program.
What Are the Clinical Implication and Future Directions Associated With Cannabis Use in Anorexia Nervosa?
Understanding the role of the endocannabinoid system (ECS) in anorexia nervosa (AN) requires longitudinal research that monitors ECS alterations during recovery. Dose-response studies using THC and CBD are critical for defining optimal doses and investigating potential beneficial interactions. In addition, specific dosing tactics based on individual characteristics may improve therapeutic efficacy and safety. To fully evaluate the risks and benefits of cannabis therapies in AN, clinical studies should include assessments for compensatory behaviors, drug use disorders, and other side effects. This will ensure informed decision-making and improve treatment outcomes.
Conclusion
Understanding the ECS' role in AN is critical for creating viable therapies. Dose-response studies and longitudinal research can shed light on cannabis therapy's potential benefits and hazards. In clinical studies, identifying undesirable effects and compensatory actions is critical for making informed decisions. Future research should focus on individualized dosing regimens and detailed evaluations to improve AN treatment outcomes.
